The market outlook for OXLUMO reflects a positive trajectory in both market performance and therapeutic potential for treating primary hyperoxaluria type 1. The drug generated approximately USD 167 ...

YolTech Therapeutics, a clinical-stage in vivo gene editing company committed to pioneering the next generation of precision genetic medicines, today reported positive results from the ongoing ...